FDA Awards Priority Review Voucher to Biomarin Pharmaceuticals for Brineura Rare Pediatric Disease Product

Summary

The FDA is issuing a priority review voucher to Biomarin Pharmaceuticals Inc. for its rare pediatric disease product Brineura, following the company's approval under the FD&C Act and FDASIA. The voucher is awarded to sponsors of approved rare pediatric disease product applications that meet specific criteria.